The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 28, 2023

Filed:

Jun. 05, 2020
Applicant:

Argenx Bv, Ghent, BE;

Inventors:

Filip Borgions, Herk-de-Stad, BE;

Stephanie Lemoult, Copenhagen, DK;

Kris Meerschaert, Ghent, BE;

Assignee:

argenx BV, Ghent, BE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/24 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01); A61K 47/18 (2017.01); A61K 47/20 (2006.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01); A61K 39/395 (2006.01); C07K 16/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/247 (2013.01); A61K 9/0019 (2013.01); A61K 39/39591 (2013.01); A61K 47/02 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); C07K 16/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01);
Abstract

Provided are various aqueous formulations of the neonatal Fc receptor (FcRn) antagonist ARGX-113, including formulations useful as pharmaceutical compositions, methods for their preparation, devices comprising the various formulations, and uses thereof. In certain embodiments the formulations are suitable and useful for administration of ARGX-113 to a human subject. In certain embodiments the formulations are suitable and useful for subcutaneous administration of ARGX-113 to a human subject. The formulations can be used in the treatment of any condition that would benefit from inhibition of FcRn-mediated antibody recycling. Such conditions can include any one or more of various antibody-mediated autoimmune diseases, including, for example and without limitation, myasthenia gravis (MG) and immune thrombocytopenia (ITP).


Find Patent Forward Citations

Loading…